In 60 patients with intrahepatic cholangiocarcinoma a longer survival time was observed in patients with ABCG2 expression in moderately to poorly differentiated tumors, but not in well differentiated (54), and in an analysis within the Cancer Genome Atlas (TCGA) program, high expression levels of ABCG2 were associated with improved prognosis in adrenocortical carcinoma, glioblastoma and renal clear cell carcinoma (38). This evidence concerns the gene ABCG2 and intrahepatic cholangiocarcinoma.